Meta-analysis of the Correlation Between High Expression of lncRNA NEAT1 in Rectal Cancer and Pathological Features and Prognosis

NEAT1 lncRNA in Rectal Cancer: Prognosis

  • Guoxi Xu Department of Gastrointestinal Surgery, Jinjiang Municipal Hospital
  • Qiyi Lin
  • Jianpeng Pan
  • Huaishuai Wang
  • Yinlin Li
  • Yixiang Zhuang
  • Jianpeng Chen
  • Gaofeng Lin
  • Weibo Liu
Keywords: lncRNA NEAT1, Prognosis, Rectal cancer, Meta analysis

Abstract


Background: To systematically evaluate the relationship between the expression level of long noncoding RNA NEAT1 and the clinical characteristics and prognostic value of rectal cancer patients.

Methods: PubMed, EMBASE, Cochrane library database and case-control studies on the correlation between abnormal expression of lncRNA NEAT1 and prognosis of rectal cancer patients published by the American clinical trials registry before May 1, 2023 were searched. The search time was from the establishment of the database to May 30, 2023.

Results: A total of 7 case-control studies were included, including 1063 cancer patients. The results of meta-analysis showed that the high expression of lncRNA NEAT1 was significantly correlated with the degree of differentiation [or=0.45, 95%CI=0.32-0.63, P<0.01], tumor size [or=0.59, 95%CI=0.42-0.82, P<0.01], and overall survival [HR=1.34, 95%CI=1.21-1.48, P<0.001]; However, it was not associated with gender [or = 1.23, 95%CI = 0.88-1.72, P=0.23] and lymph node metastasis [or = 0.87, 95%CI = 0.45-1.66, P=0.67].

Conclusion: The high expression of lncRNA NEAT1 may be a risk factor for poor prognosis in patients with malignant tumors, and lncRNA NEAT1 can be used as a potential biomarker to evaluate its prognosis.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-Cancer J Clin 2018; 68(6): 394-424.
2. Wu C, Li M, Meng H, Liu Y, Niu W, Zhou Y, et al. Analysis of status and countermeasures of cancer incidence and mortality in China. Sci China Life Sci 2019; 62(5): 640-7.
3. Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-Cancer J Clin 2020; 70(4): 313.
4. Gao Y, Shang S, Guo S, Li X, Zhou H, Liu H, et al. Lnc2Cancer 3.0: an updated resource for experimentally supported lncRNA/circRNA cancer associations and web tools based on RNA-seq and scRNA-seq data. Nucleic Acids Res 2021; 49(D1): D1251-8.
5. Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003; 22(39): 8031-41.
6. Hutchinson JN, Ensminger AW, Clemson CM, Lynch CR, Lawrence JB, Chess A. A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains. Bmc Genomics 2007; 8: 39.
7. Klec C, Prinz F, Pichler M. Involvement of the long noncoding RNA NEAT1 in carcinogenesis. Mol Oncol 2019; 13(1): 46-60.
8. Lo PK, Wolfson B, Zhou Q. Cellular, physiological and pathological aspects of the long non-coding RNA NEAT1. Front Biol (Beijing) 2016; 11(6): 413-26.
9. Yu X, Li Z, Zheng H, Chan MT, Wu WK. NEAT1: A novel cancer-related long non-coding RNA. Cell Proliferat 2017; 50(2): e12329.
10. Li Y, Li Y, Chen W, He F, Tan Z, Zheng J, et al. NEAT expression is associated with tumor recurrence and unfavorable prognosis in colorectal cancer. Oncotarget 2015; 6(29): 27641-50.
11. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj-Brit Med J 2011; 343: d5928.
12. Peng W, Wang Z, Fan H. LncRNA NEAT1 Impacts Cell Proliferation and Apoptosis of Colorectal Cancer via Regulation of Akt Signaling. Pathol Oncol Res 2017; 23(3): 651-6.
13. Zhang M, Weng W, Zhang Q, Wu Y, Ni S, Tan C, et al. The lncRNA NEAT1 activates Wnt/beta-catenin signaling and promotes colorectal cancer progression via interacting with DDX5. J Hematol Oncol 2018; 11(1): 113.
14. Luo Y, Chen JJ, Lv Q, Qin J, Huang YZ, Yu MH, et al. Long non-coding RNA NEAT1 promotes colorectal cancer progression by competitively binding miR-34a with SIRT1 and enhancing the Wnt/beta-catenin signaling pathway. Cancer Lett 2019; 440-441: 11-22.
15. Yu HM, Wang C, Yuan Z, Chen GL, Ye T, Yang BW. LncRNA NEAT1 promotes the tumorigenesis of colorectal cancer by sponging miR-193a-3p. Cell Proliferat 2019; 52(1): e12526.
16. Guo T, Liu DF, Peng SH, Xu AM. ALKBH5 promotes colon cancer progression by decreasing methylation of the lncRNA NEAT1. Am J Transl Res 2020; 12(8): 4542-9.
17. Wang Y, Zhang D, Zhang C, Sun Y. The Diagnostic and Prognostic Value of Serum lncRNA NEAT1 in Colorectal Cancer. Cancer Manag Res 2020; 12: 10985-92.
18. Silva J, Da CMP. Non-Coding RNAs in the Therapeutic Landscape of Pathological Cardiac Hypertrophy. Cells-Basel 2022; 11(11): 1805.
19. Feng Y, Gao L, Cui G, Cao Y. LncRNA NEAT1 facilitates pancreatic cancer growth and metastasis through stabilizing ELF3 mRNA. Am J Cancer Res 2020; 10(1): 237-48.
Published
2024/03/03
Section
Original paper